<p>Oric Pharmaceuticals, Inc.（納斯達克代碼：ORIC - 獲取免費報告）週三股價下跌 6.8%。該股最低交易價為 10.97 美元，最後交易價為 11.2850 美元。在午盤交易中，共成交 592,162 股，較平均交易量 1,798,275 股下降 67%。該股此前收盤價為 12.11 美元。</p>
<p>獲取 <strong>Oric Pharmaceuticals</strong> 的提醒：</p>
<h2>分析師評級調整</h2>
<p>多位分析師對該公司發表了看法。Piper Sandler 在 1 月 7 日的研究報告中開始覆蓋 Oric Pharmaceuticals，給予 “增持” 評級和 22.00 美元的目標價。華爾街 Zen 在 11 月 23 日的研究報告中將 Oric Pharmaceuticals 的評級從 “持有” 下調至 “賣出”。摩根大通在 11 月 18 日的報告中將 Oric Pharmaceuticals 的目標價從 17.00 美元上調至 20.00 美元，並給予 “增持” 評級。富國銀行在 12 月 8 日的研究報告中將 Oric Pharmaceuticals 的目標價從 19.00 美元上調至 25.00 美元，並給予 “增持” 評級。最後，Oppenheimer 在 11 月 14 日的研究報告中將 Oric Pharmaceuticals 的目標價從 12.00 美元上調至 15.00 美元，並給予該股 “跑贏大盤” 評級。共有 11 位研究分析師對該股給予 “買入” 評級，2 位給予 “持有” 評級，1 位給予 “賣出” 評級。根據 MarketBeat 的數據，該股的平均評級為 “適度買入”，平均目標價為 19.90 美元。</p>
<p><strong>查看我們關於 Oric Pharmaceuticals 的最新股票報告</strong></p>
<h2>Oric Pharmaceuticals 股價下跌 6.1%</h2>
<p>該公司的 50 日簡單移動平均線為 10.10 美元，200 日簡單移動平均線為 10.93 美元。該公司的市值為 11.1 億美元，市盈率為-6.59，貝塔值為 1.36。</p>
<p>Oric Pharmaceuticals（納斯達克代碼：ORIC - 獲取免費報告）最近在 11 月 13 日發佈了季度財報。該公司報告每股收益（EPS）為-0.33 美元，超出市場共識預期的-0.41 美元，超出幅度為 0.08 美元。平均而言，賣方分析師預計 Oric Pharmaceuticals, Inc.在當前財年將發佈-2.17 美元的每股收益。</p>
<h2>Oric Pharmaceuticals 的內部交易</h2>
<p>在其他消息中，首席執行官 Jacob Chacko 在 12 月 16 日的交易中出售了 33,374 股 Oric Pharmaceuticals 的股票。該股票以平均價格 9.06 美元出售，總價值為 302,368.44 美元。交易完成後，首席執行官持有 581,711 股公司股票，價值為 5,270,301.66 美元。此次交易使其持股減少了 5.43%。該交易已在向證券交易委員會提交的文件中披露，文件可通過 SEC 網站獲取。此外，內部人士 Pratik S. Multani 在 12 月 16 日的交易中出售了 10,720 股該公司的股票。該股票以平均價格 9.06 美元出售，總交易額為 97,123.20 美元。出售後，內部人士持有 68,149 股公司股票，價值約為 617,429.94 美元。這代表其持股減少了 13.59%。該銷售的 SEC 文件提供了更多信息。在過去三個月中，內部人士共出售了 54,814 股公司股票，價值為 496,615 美元。內部人士持有公司股票的比例為 5.55%。</p>
<h2>機構資金流入和流出</h2>
<p>對該公司的持股情況，最近對沖基金進行了調整。Zurcher Kantonalbank Zurich Cantonalbank 在第四季度購買了 Oric Pharmaceuticals 的新股份，價值為 135,000 美元。Mirae Asset Global Investments Co. Ltd.在第四季度將其在 Oric Pharmaceuticals 的持股增加了 26.0%。Mirae Asset Global Investments Co. Ltd.現在擁有 4,732 股公司股票，價值 39,000 美元，此前在上個季度又購買了 977 股。Tema Etfs LLC 在第四季度購買了 Oric Pharmaceuticals 的新股份，價值約為 228,000 美元。Hennion &amp; Walsh Asset Management Inc.在第四季度將其在 Oric Pharmaceuticals 的持股增加了 15.7%。Hennion &amp; Walsh Asset Management Inc.現在擁有 170,072 股公司股票，價值 1,391,000 美元，此前在上個季度又購買了 23,024 股。最後，SG Americas Securities LLC 在第四季度將其在 Oric Pharmaceuticals 的持股增加了 127.6%。SG Americas Securities LLC 現在擁有 41,016 股公司股票，價值 336,000 美元，此前在該期間又購買了 22,993 股。對沖基金和其他機構投資者持有公司 95.05% 的股票。</p>
<h2>Oric Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Oric Pharmaceuticals, Inc.是一家總部位於加利福尼亞州南舊金山的臨牀階段生物製藥公司。該公司致力於發現和開發旨在克服實體腫瘤腫瘤學中耐藥機制的小分子治療藥物。其研究工作重點是識別新靶點並推進精準醫療，以便在標準療法失效時恢復或增強患者的反應。</p>
<p>該公司的產品管線包括主要候選藥物 ORIC-101，這是一種選擇性、口服可用的糖皮質激素受體拮抗劑，目前正在對獲得化療和激素藥物耐藥的實體腫瘤患者進行 1/2 期臨牀試驗。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Oric Pharmaceuticals 更好</li>
<li>您的簽名缺失 - 請在為時已晚之前採取行動</li>
<li>什麼費用可以從資本利得税中扣除？</li>
<li>請勿刪除，立即閲讀</li>
<li>1933 年的退款：特朗普的重置可能創造即時財富</li>
<li>在週一上午 9:30 購買該股票！</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 Oric Pharmaceuticals 嗎？</h2>
<p>在考慮 Oric Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Oric Pharmaceuticals 並不在名單上。</p>
<p>雖然 Oric Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

紐交所高增長板生物技術指數 ETF - First Trust

醫療業 ETF - SPDR

標普全球醫療股指數 ETF - iShares

<p>Oric Pharmaceuticals（納斯達克代碼：ORIC）股價下跌 6.8%，至 11.2850 美元，交易量下降 67%。分析師的評級意見不一，Piper Sandler 首次覆蓋給予 “增持” 評級，目標價為 22 美元，而 Wall Street Zen 則下調至 “賣出”。該股票的平均評級為 “適度買入”，目標價為 19.90 美元。近期的內部銷售和機構投資表明交易活躍。Oric Pharmaceuticals 專注於開發針對實體腫瘤的治療藥物，報告的季度每股收益為（-0.33 美元），超出預期</p>

<p>Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report)'s share price fell 6.8% on Wednesday . The stock traded as low as $10.97 and last traded at $11.2850. 592,162 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 1,798,275 shares. The stock had previously closed at $12.11.</p>
<div class="lb-trans"><p>Oric Pharmaceuticals, Inc.（納斯達克代碼：ORIC - 獲取免費報告）週三股價下跌 6.8%。該股最低交易價為 10.97 美元，最後交易價為 11.2850 美元。在午盤交易中，共成交 592,162 股，較平均交易量 1,798,275 股下降 67%。該股此前收盤價為 12.11 美元。</p>
</div><p>Get <strong>Oric Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Oric Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>Several analysts have weighed in on the company. Piper Sandler initiated coverage on Oric Pharmaceuticals in a research report on Wednesday, January 7th. They issued an &#34;overweight&#34; rating and a $22.00 price objective for the company. Wall Street Zen cut shares of Oric Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Sunday, November 23rd. JPMorgan Chase &amp; Co. boosted their price target on Oric Pharmaceuticals from $17.00 to $20.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, November 18th. Wells Fargo &amp; Company upped their price target on Oric Pharmaceuticals from $19.00 to $25.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, December 8th. Finally, Oppenheimer lifted their price objective on Oric Pharmaceuticals from $12.00 to $15.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, November 14th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $19.90.</p>
<div class="lb-trans"><p>多位分析師對該公司發表了看法。Piper Sandler 在 1 月 7 日的研究報告中開始覆蓋 Oric Pharmaceuticals，給予 “增持” 評級和 22.00 美元的目標價。華爾街 Zen 在 11 月 23 日的研究報告中將 Oric Pharmaceuticals 的評級從 “持有” 下調至 “賣出”。摩根大通在 11 月 18 日的報告中將 Oric Pharmaceuticals 的目標價從 17.00 美元上調至 20.00 美元，並給予 “增持” 評級。富國銀行在 12 月 8 日的研究報告中將 Oric Pharmaceuticals 的目標價從 19.00 美元上調至 25.00 美元，並給予 “增持” 評級。最後，Oppenheimer 在 11 月 14 日的研究報告中將 Oric Pharmaceuticals 的目標價從 12.00 美元上調至 15.00 美元，並給予該股 “跑贏大盤” 評級。共有 11 位研究分析師對該股給予 “買入” 評級，2 位給予 “持有” 評級，1 位給予 “賣出” 評級。根據 MarketBeat 的數據，該股的平均評級為 “適度買入”，平均目標價為 19.90 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Oric Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Oric Pharmaceuticals 的最新股票報告</strong></p>
</div><h2>Oric Pharmaceuticals Stock Down 6.1%</h2>
<div class="lb-trans"><h2>Oric Pharmaceuticals 股價下跌 6.1%</h2>
</div><p>The business has a fifty day simple moving average of $10.10 and a 200-day simple moving average of $10.93. The firm has a market cap of $1.11 billion, a P/E ratio of -6.59 and a beta of 1.36.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為 10.10 美元，200 日簡單移動平均線為 10.93 美元。該公司的市值為 11.1 億美元，市盈率為-6.59，貝塔值為 1.36。</p>
</div><p>Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.08. On average, sell-side analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Oric Pharmaceuticals（納斯達克代碼：ORIC - 獲取免費報告）最近在 11 月 13 日發佈了季度財報。該公司報告每股收益（EPS）為-0.33 美元，超出市場共識預期的-0.41 美元，超出幅度為 0.08 美元。平均而言，賣方分析師預計 Oric Pharmaceuticals, Inc.在當前財年將發佈-2.17 美元的每股收益。</p>
</div><h2>Insider Transactions at Oric Pharmaceuticals</h2>
<div class="lb-trans"><h2>Oric Pharmaceuticals 的內部交易</h2>
</div><p>In other news, CEO Jacob Chacko sold 33,374 shares of Oric Pharmaceuticals stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total value of $302,368.44. Following the completion of the transaction, the chief executive officer owned 581,711 shares of the company's stock, valued at $5,270,301.66. The trade was a 5.43% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, insider Pratik S. Multani sold 10,720 shares of the firm's stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total transaction of $97,123.20. Following the sale, the insider owned 68,149 shares of the company's stock, valued at approximately $617,429.94. This represents a 13.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 54,814 shares of company stock valued at $496,615. Insiders own 5.55% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席執行官 Jacob Chacko 在 12 月 16 日的交易中出售了 33,374 股 Oric Pharmaceuticals 的股票。該股票以平均價格 9.06 美元出售，總價值為 302,368.44 美元。交易完成後，首席執行官持有 581,711 股公司股票，價值為 5,270,301.66 美元。此次交易使其持股減少了 5.43%。該交易已在向證券交易委員會提交的文件中披露，文件可通過 SEC 網站獲取。此外，內部人士 Pratik S. Multani 在 12 月 16 日的交易中出售了 10,720 股該公司的股票。該股票以平均價格 9.06 美元出售，總交易額為 97,123.20 美元。出售後，內部人士持有 68,149 股公司股票，價值約為 617,429.94 美元。這代表其持股減少了 13.59%。該銷售的 SEC 文件提供了更多信息。在過去三個月中，內部人士共出售了 54,814 股公司股票，價值為 496,615 美元。內部人士持有公司股票的比例為 5.55%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Oric Pharmaceuticals during the fourth quarter valued at $135,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Oric Pharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company's stock valued at $39,000 after purchasing an additional 977 shares during the last quarter. Tema Etfs LLC bought a new position in Oric Pharmaceuticals during the fourth quarter valued at approximately $228,000. Hennion &amp; Walsh Asset Management Inc. boosted its holdings in Oric Pharmaceuticals by 15.7% in the fourth quarter. Hennion &amp; Walsh Asset Management Inc. now owns 170,072 shares of the company's stock worth $1,391,000 after purchasing an additional 23,024 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in Oric Pharmaceuticals by 127.6% in the 4th quarter. SG Americas Securities LLC now owns 41,016 shares of the company's stock worth $336,000 after purchasing an additional 22,993 shares during the period. Hedge funds and other institutional investors own 95.05% of the company's stock.</p>
<div class="lb-trans"><p>對該公司的持股情況，最近對沖基金進行了調整。Zurcher Kantonalbank Zurich Cantonalbank 在第四季度購買了 Oric Pharmaceuticals 的新股份，價值為 135,000 美元。Mirae Asset Global Investments Co. Ltd.在第四季度將其在 Oric Pharmaceuticals 的持股增加了 26.0%。Mirae Asset Global Investments Co. Ltd.現在擁有 4,732 股公司股票，價值 39,000 美元，此前在上個季度又購買了 977 股。Tema Etfs LLC 在第四季度購買了 Oric Pharmaceuticals 的新股份，價值約為 228,000 美元。Hennion &amp; Walsh Asset Management Inc.在第四季度將其在 Oric Pharmaceuticals 的持股增加了 15.7%。Hennion &amp; Walsh Asset Management Inc.現在擁有 170,072 股公司股票，價值 1,391,000 美元，此前在上個季度又購買了 23,024 股。最後，SG Americas Securities LLC 在第四季度將其在 Oric Pharmaceuticals 的持股增加了 127.6%。SG Americas Securities LLC 現在擁有 41,016 股公司股票，價值 336,000 美元，此前在該期間又購買了 22,993 股。對沖基金和其他機構投資者持有公司 95.05% 的股票。</p>
</div><h2>Oric Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Oric Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.</p>
<div class="lb-trans"><p>Oric Pharmaceuticals, Inc.是一家總部位於加利福尼亞州南舊金山的臨牀階段生物製藥公司。該公司致力於發現和開發旨在克服實體腫瘤腫瘤學中耐藥機制的小分子治療藥物。其研究工作重點是識別新靶點並推進精準醫療，以便在標準療法失效時恢復或增強患者的反應。</p>
</div><p>The company's pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.</p>
<div class="lb-trans"><p>該公司的產品管線包括主要候選藥物 ORIC-101，這是一種選擇性、口服可用的糖皮質激素受體拮抗劑，目前正在對獲得化療和激素藥物耐藥的實體腫瘤患者進行 1/2 期臨牀試驗。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Oric Pharmaceuticals</li>
<li>Your Signature Is Missing – Act Before It’s Too Late</li>
<li>What Expenses Can Be Deducted From Capital Gains Tax?</li>
<li>Do not delete, read immediately</li>
<li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li>
<li>Buy This Stock at 9:30 AM on MONDAY!</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Oric Pharmaceuticals 更好</li>
<li>您的簽名缺失 - 請在為時已晚之前採取行動</li>
<li>什麼費用可以從資本利得税中扣除？</li>
<li>請勿刪除，立即閲讀</li>
<li>1933 年的退款：特朗普的重置可能創造即時財富</li>
<li>在週一上午 9:30 購買該股票！</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Oric Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Oric Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Oric Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Oric Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Oric Pharmaceuticals 並不在名單上。</p>
</div><p>While Oric Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Oric Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Oric Pharmaceuticals (NASDAQ:ORIC)  Shares Down 6.8%   - Time to Sell?

Market Beat

ORIC Pharmaceuticals

動態生物技術與基因組 ETF - Invesco

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

美國制藥 ETF - iShares

醫療業 ETF - Vanguard

2 倍做多納斯達克生物技術 ETF - ProShares

醫藥突破 ETF - ALPS

基因改革 ETF - ARK

ORIC Pharmaceuticals（納斯達克代碼：ORIC）股價下跌 6.8% - 現在是賣出的時候嗎？